NEWS
Fiscal Year 2019 - Record year points to increasing growth dynamics
13. Mar 2020
- Sales pass 300-million mark for the first time at 313.7 million CHF
- EBIT margin rises to 19.9%, EBITDA margin to 27.8%
- Net income up sharply to 54.2 million CHF
- Initial successes in oligonucleotide market
- Growth targets raised thanks to rising demand
- Proposed dividend increase to 3.00 CHF per share